ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells

Liu, Zongcai; Ning, Fen; Cai, Yanna; Sheng, Huiying; Zheng, Ruidan; Yin, Xi; Lu, Zhikun; Su, Ling; Chen, Xiaodan; Zeng, Chunhua; Wang, Haifang*; Liu, Li*广州医学院; 南方医科大学
Cancer Communications2021-1DOI: 10.1002/cac2.12117
26被引7阅读
引用收藏
分享

摘要

Background Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently activated in HCC and plays important roles in tumorigenesis. However, its role in HCC immunity is still largely unknown. This study aimed to investigate the impact of EGFR signaling on programmed death-ligand 1 (PD-L1) and human leukocyte antigen class-I (HLA-I) expression in HCC cells and its underlying mechanisms. @@@ Methods The expression of phosphorylated EGFR (p-EGFR), PD-L1, and HLA-I (HLA-ABC) in HCC specimens was detected by immunohistochemistry, and their correlations were analyzed. PD-L1 and HLA-ABC expression in EGFR-activated HCC cells were detected by quantitative real-time PCR, Western blotting, and flow cytometry, and T cell-mediated lysis was performed to test the immunosuppressive effects of PD-L1 and HLA-ABC alterations in HCC cells. Furthermore, the underlying mechanisms of EGFR activation-induced PD-L1 up-regulation and HLA-ABC down-regulation were explored by animal experiments, luciferase reporter assay, and gene gain- and loss-of-function studies. @@@ Results p-EGFR was positively correlated with PD-L1 and negatively correlated with HLA-ABC expression in HCCs. EGFR activation by its ligand EGF up-regulated PD-L1 and down-regulated HLA-ABC in HCC cells, which was functionally important and could be abolished by the EGFR inhibitor, gefitinib, both in vitro and in vivo. Mechanistically, enhanced P38 mitogen-activated protein kinase (MAPK) activation down-regulated microRNA-675-5p (miR-675-5p) and up-regulated glycolysis-related enzyme hexokinase 2 (HK2); miR-675-5p down-regulation enhanced the stability of PD-L1 mRNA probably via the 3'-untranslated region (3'-UTR) of PD-L1 and thereby caused PD-L1 accumulation, and HK2 up-regulation enhanced aerobic glycolysis and mediated a decrease in HLA-ABC. @@@ Conclusions The EGFR-P38 MAPK axis could up-regulate PD-L1 through miR-675-5p and down-regulate HLA-ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy.

学科与关键词

关键词
EGFR signalingP38 MAPKPD&#8208L1HLA&#8208ABCmiR&#8208675&#82085pHexokinase&#82082Hepatocellular carcinoma
相关
加载中…
  • microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3
    Li, Yaqin; Zhou, Tao; Cheng, Xianyi; Li, Dezhi; Zhao, Meng; Zheng, Wei, V*Bioengineered, 2022, 13(3): 4730-4743.被引 14
  • PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
    Guo, Shuang; Wang, Xinyue; Zhou, Hanxiao; Gao, Yue; Wang, Peng; Zhi, Hui; Sun, Yue; Zhang, Yakun; Gan, Jing; Xiao, Yun*; Ning, Shangwei*Biomolecules, 2022, 12(9): 1226.被引 4
  • Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
    Mou, Haibo; Yang, Qiu-an; Yu, Lanfang; Wang, Ting; Liu, Kui; Shen, Rong; Pan, Xuedong; Dai, Yi; Wan, Qing; Zhou, Fangling; Qian, Lili; Chen, Donglin; Yau, Thomas; Dong, Xiaowei; Wang, Xuemei*; Wang, Shuang*Journal of Gastroenterology and Hepatology, 2021, 36(9): 2601-2609.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Communications
发表日期
2021-01
卷期
第 41 卷, 第 1 期
页码
62-78
DOI
10.1002/cac2.12117
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81602493, 81902926, 31600746]; Natural Science Foundation of Guangdong Frovince [2018030310305]; Fund from Guangzhou Women and Children's Medical Center/Internal Medicine Department [NKE-PRE-2019-008]

作者

  • L

    Liu, Zongcai (第一作者)

    guangzhou med univ · guangzhou women & childrens med ctr

  • N

    Ning, Fen

    guangzhou med univ · guangzhou women & childrens med ctr

查看全部 12 位作者收起作者
  • C

    Cai, Yanna

    guangzhou med univ · guangzhou women & childrens med ctr

  • S

    Sheng, Huiying

    guangzhou med univ · guangzhou women & childrens med ctr

  • Z

    Zheng, Ruidan

    guangzhou med univ · guangzhou women & childrens med ctr

  • Y

    Yin, Xi

    guangzhou med univ · guangzhou women & childrens med ctr

  • L

    Lu, Zhikun

    guangzhou med univ · guangzhou women & childrens med ctr

  • S

    Su, Ling

    guangzhou med univ · guangzhou women & childrens med ctr

  • C

    Chen, Xiaodan

    guangzhou med univ · guangzhou women & childrens med ctr

  • Z

    Zeng, Chunhua

    guangzhou med univ · guangzhou women & childrens med ctr

  • W

    Wang, Haifang (通讯)

    southern med univ

  • L

    Liu, Li (通讯)

    guangzhou med univ · guangzhou women & childrens med ctr

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417